Please Wait
Applying Filters...
menu
    • menu
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    IMIPENEM; CILASTATIN

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,345Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    26/09/2024 ACS DOBFAR SPA
    Italy
    		 ACS DOBFAR S. p. A. 304MF10136 Cilastatin Sodium 2022-10-05 2022-10-05 Viale Addetta, 4/12, 20067 Tribiano (Milan) Italy
    26/09/2024 Choongwae Pharma Corporation JW Pharmaceutical Corporation 219MF10001 Cilastatin Sodium 2007-01-18 2012-05-11 2477, Nambusunhwan-ro Seocho-gu, Seoul, Republic of Korea